SCYX · XBRL financial data

SCYNEXIS financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (SCYX's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue from contracts with customers	1,761	5,797*	1,373	736	660	977*	257	1,364	334	year only	0	235
Research and development	6,466	10,586*	7,212	6,807	8,073	4,314*	5,141	7,141	5,452	4,545*	12,351	3,891
Selling, general and administrative	5,014	3,592*	3,669	3,166	2,907	4,716*	3,726	3,784	3,287	3,580*	4,588	4,119
Total operating expenses	11,859	28,862*	10,881	9,973	10,980	9,030*	8,867	10,925	8,739	8,125*	16,939	8,010
Operating income (loss)	(10,098)	(23,065)*	(9,508)	(9,237)	(10,320)	(8,053)*	(8,610)	(9,561)	(8,405)	10,521*	(16,939)	(7,775)
Interest expense	212	222*	205	197	213	211*	173	0	0	0*	0	0
Income tax expense (benefit)	0	138*	531	0	(395)	23*	0	0	0	0*	—	—
Net income (loss)	(1,757)	(19,586)*	411	(14,458)	(2,808)	(4,433)*	(5,391)	(6,885)	(8,591)	12,258*	(21,299)	7,397
Earnings per share, basic‡ USD per share	(0.32)	(3.28)*	0.08	(2.40)	(0.48)	(0.72)*	(0.88)	(1.12)	(1.36)	1.92*	(3.36)	0.63
Earnings per share, diluted‡ USD per share	(0.32)	—	0.08	(2.40)	(0.48)	(0.72)*	(0.88)	(1.12)	(1.36)	1.92*	(3.36)	0.63
Weighted average shares, basic‡ thousands of shares	5,987	5,990*	6,031	6,064	6,077	6,084*	6,179	6,219	6,237	6,330*	6,370	11,824
Weighted average shares, diluted‡ thousands of shares	5,987	5,999*	6,071	6,064	6,077	6,045*	6,179	6,219	6,237	6,330*	6,370	11,824

‡ Per-share figures and share counts are adjusted for the 1-for-8 stock split (May 2026); filings made before it reported them unadjusted.

Balance sheet

CSV

Fiscal quarters (SCYX's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	44,071	34,050	35,482	25,994	28,730	16,051	6,942	11,020	14,797	21,259	36,671	10,487
Short-term investments	44,001	40,312	44,762	47,044	40,098	43,249	33,665	33,765	23,131	18,772	22,592	43,596
Accounts receivable	2,245	0	—	—	—	—	—	—	—	—	—	—
Inventory	13,114	0	—	—	—	—	—	—	—	—	—	—
Prepaid and other current assets	3,172	5,548	1,583	1,418	1,538	2,184	1,454	1,578	686	263	919	1,540
Total current assets	128,641	102,116	101,673	94,578	80,463	72,181	52,221	56,498	48,694	40,374	62,691	56,236
Right-of-use asset	2,425	2,364	2,300	2,233	2,163	2,090	2,013	1,934	1,851	1,764	1,673	1,578
Total assets	148,546	128,412	118,254	107,806	99,038	90,643	67,915	60,694	51,071	59,027	77,626	74,970
Accounts payable	3,490	7,149	8,918	5,350	4,955	4,569	4,260	6,172	3,467	2,225	5,632	3,265
Accrued liabilities	9,543	7,495	4,601	5,498	5,508	3,793	2,630	2,477	2,774	2,791	1,529	2,034
Total current liabilities	16,790	16,303	27,349	25,233	25,719	24,099	8,957	10,863	8,469	5,734	15,900	5,825
Lease liability, non-current	2,673	2,581	2,487	2,388	2,284	2,175	2,062	1,945	1,821	1,692	1,557	1,419
Total liabilities	56,555	55,450	44,149	47,400	40,509	35,566	17,383	16,227	14,641	9,651	36,319	8,040
Accumulated deficit	(335,661)	(355,247)	(354,836)	(369,294)	(372,102)	(376,535)	(381,926)	(388,811)	(397,402)	(385,144)	(406,443)	(399,046)
Total stockholders' equity	91,991	72,962	74,105	60,406	58,529	55,077	50,532	44,467	36,430	49,376	41,307	66,930
Total liabilities and equity	148,546	128,412	118,254	107,806	99,038	90,643	67,915	60,694	51,071	59,027	77,626	74,970
Common shares outstanding (cover page)‡ thousands of shares	4,651	4,719	4,722	4,732	4,744	4,873	4,878	5,241	5,246	5,583	9,930	9,950

‡ Per-share figures and share counts are adjusted for the 1-for-8 stock split (May 2026); filings made before it reported them unadjusted.

Cash flows

CSV

Fiscal quarters (SCYX's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(1,757)	(19,586)*	411	(14,458)	(2,808)	(4,433)*	(5,391)	(6,885)	(8,591)	12,258*	(21,299)	7,397
Stock-based compensation	632*	557*	705	759*	901*	981*	819	820*	526*	687*	580	568*
Net cash from operating activities	12,419*	(7,735)*	(4,007)	(10,860)*	765*	(9,907)*	(7,465)	(7,495)*	(8,724)*	18,401*	(8,101)	(14,885)*
Net cash from investing activities	(26,341)*	(2,152)*	5,454	1,372*	1,941*	(2,617)*	12,440	11,273*	12,417*	(11,824)*	(525)	(24,758)*
Proceeds from issuing common stock	(4)*	0*	—	—	—	0*	—	—	—	1*	—	—
Net cash from financing activities	34*	(135)*	(15)	0*	31*	(155)*	(14,084)	0*	29*	(115)*	24,038	13,459*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Scynexis	10,487	235	(14,885)*	9.9M	3.6 quarters	Q2 FY26 10-QJun 30, 2026
Palatin Technologies	7,492	301*	(2,690)*	1.8M	2.8 quarters	Q4 FY26 10-KJun 30, 2026
Pulmatrix	2,168	not reported	(1,106)*	3.7M	2.0 quarters	Q2 FY26 10-QJun 30, 2026
Scorpius Holdings	582	not reported	(2,917)*	61.1M	0.2 quarters	Q3 FY25 10-QSep 30, 2025
Curis	5,073	0	(9,646)*	2.1M	0.5 quarters	Q2 FY26 10-QJun 30, 2026
Kala Bio	229	not reported	(1,535)*	19.3M	4.7 quarters	Q2 FY26 10-QJun 30, 2026
Lexaria Bioscience	3,500	0	(1,635)*	24.8M	2.2 quarters	Q3 FY26 10-QMay 31, 2026
Outlook Therapeutics	11,242	not reported	(21,011)*	243.4M	0.5 quarters	Q3 FY26 10-QJun 30, 2026
Dyadic International	1,425	961	(1,818)*	36.4M	1.7 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.